European Union - English - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - avandamet is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

European Union - English - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone - diabetes mellitus, type 2 - drugs used in diabetes - rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy-in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with-metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin-a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylureaas triple oral therapy in combination with-metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy (see section 4.4).

Malta - English - Medicines Authority

smithkline beecham plc - amoxicillin 400 mg/5ml, clavulanic acid 57 mg/5ml - powder for oral suspension

Malta - English - Medicines Authority

smithkline beecham limited - haemophilus influenzae b; tetanus toxoid - powder and solvent for solution for infusion - haemophilus influenzae b 25 µg; tetanus toxoid 25 µg - vaccines

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 459.17mg/5ml eqv amoxycillin; potassium clavulanate 67.9mg/5ml eqv clavulanic acid - powder, for suspension - 400 mg/5 ml - amoxycillin trihydrate 459.17mg/5ml eqv amoxycillin 400 mg/5 ml; potassium clavulanate 67.9mg/5ml eqv clavulanic acid 57 mg/5 ml

Malta - English - Medicines Authority

beecham group plc - phenylephrine hydrochloride 10 mg, paracetamol 600 mg - powder for oral solution

Malta - English - Medicines Authority

beecham group plc - phenylephrine hydrochloride 10 mg, paracetamol 600 mg - powder for oral solution

Malta - English - Medicines Authority

beecham group plc - phenylephrine 10 mg, ascorbic acid 40 mg, paracetamol 1000 mg - powder for oral solution

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 229.58mg/5ml eqv amoxycillin; potassium clavulanate 33.95mg/5ml eqv clavulanic acid - powder, for suspension - 200 mg/5 ml - amoxycillin trihydrate 229.58mg/5ml eqv amoxycillin 200 mg/5 ml; potassium clavulanate 33.95mg/5ml eqv clavulanic acid 28.5 mg/5 ml